Endocrine Testing Market: By Technology (Tandem Mass Spectrometry, Immunoassay, Monoclonal, Sensor & Clinical Chemistry Technologies), By Disorder Categories, By End User

Endocrine Testing Market in the Global Industry Landscape

Endocrine testing is done to get information related to the hormone level in the body the disorders related to them. In the past years, the elucidation of the pathophysiology related to several endocrine disorders is successful through the development of radio-immunoassay and various other diagnostic tools. This has led the clinicians to make faster and accurate diagnosis. The diseases such as thyroid disorders, osteoporosis, diabetes, and hyperparathyroidism which tends to increase their frequency with the advent of age and other factors are the ones most benefitted with the new technologies. Moreover, the effective and specific cure therapies such as the oral sulfonylureas for both hormonal and non-hormonal treatments for osteoporosis and also diabetes have certainly enhanced the quality and longevity of life of older individuals suffering from these diseases. The newer tests varieties provides the ability to monitor the therapeutic effectiveness from a closer view.

Our Global Endocrine Testing Market can be segmented on the following basis:

Based on Technology

• Tandem Mass Spectrometry
• Immunoassay
• Monoclonal and Polyclonal Antibody Technologies
• Sensor Technologies
• Clinical Chemistry Technologies

Based on Disorder Categories

• Adrenocortical Function
• Perturbation Tests
• Diagnostic Profiles
• Thyroid Function
• Hypothalamic and Pituitary Function
• Growth and Growth Hormone
• Metabolic and Gastrointestinal Disorders
• Others (Gonadal Function, etc.)

Based on End User

• Hospitals/Critical Care Centers
• Diagnostics Labs
• Research Laboratories

By Geography

• North America (US, Canada) {Market Share (%), Market Size (USD Billion)} Endocrine Testing Market
• Europe (UK, France, Italy, Germany, Spain, Sweden, Russia, Netherlands, Norway and Rest of Europe) {Market Share (%), Market Size (USD Billion)} Endocrine Testing Industry
• The Middle East and Africa (GCC Countries, North Africa, South Africa and Rest of Middle East & Africa) {Market Share (%), Market Size (USD Billion)} Endocrine Testing Market
• Latin America (Brazil, Mexico and Rest of Latin America) {Market Share (%), Market Size (USD Billion)} Endocrine Testing Market
• Asia Pacific (China, Japan, India, Singapore, South Korea, Australia and Rest of Asia-Pacific) {Market Share (%), Market Size (USD Billion)} Endocrine Testing Market

Global Endocrine Testing Market Outlook comprises of the following data:

• Endocrine testing market size and market compounded annual growth rate, 2017-2025
• Number of endocrine testing cases by region, 2017-2025
• Number of New Entrants in the endocrine testing market, 2017-2025
• Number of new clinically tested and approved endocrine tests types, 2017-2018

North America endocrine testing market is the leading the way in terms of revenue generation. The high healthcare investments in the region coupled with positive regulatory framework and high reimbursement scenario are the major driving factors for the growth of endocrine testing market in North America.

The U.S. Food and Drug Administration (FDA) in early 2018 approved a new continuous glucose monitoring (CGM) system applicable for diabetic people between the age group of 14 to 75 years. The company Medtronic, is witnessed to market the system with a name as ‘Guardian Connect’, globally the first smart system that can help diabetic people to keep a real-time track of high and low glucose events and stay proactive. The Guardian Connect system has helped the people indulged with multiple daily injections (MDI) towards more actively and preemptively manage their diabetes.

Expert Analysis: Various endocrine testing technologies are under trial to treat hormonal disorders. Development of new test methods has undergone intensive research over the past decade. And still the developers are addressing the question that whether the system is capable of resolving complexities of the endocrine system as per the regulatory health and ecological risk assessments.